Sinopharm Group Co ( (HK:1099) ) has shared an update.
Sinopharm Group Co. Ltd. announced the unaudited financial results for its subsidiary, Sinopharm Accord, for the first quarter ended March 31, 2025. The company reported a decline in revenue by 4.17% and a 15.63% decrease in net profit attributable to shareholders compared to the same period last year. Additionally, there was a significant drop in net cash flow from operating activities by 186.57%. Despite these declines, the total assets increased by 5.19%, indicating a potential for long-term growth.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading company in the pharmaceutical industry, primarily involved in the distribution and retail of pharmaceutical and healthcare products. The company operates through its subsidiary, China National Accord Medicines Corporation Ltd., which is listed on the Shenzhen Stock Exchange.
YTD Price Performance: -19.78%
Average Trading Volume: 2,115
Technical Sentiment Signal: Buy
Current Market Cap: $7.23B
For detailed information about 1099 stock, go to TipRanks’ Stock Analysis page.